Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer.

Trial Profile

Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Docetaxel; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.
    • 02 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Mar 2013 University Hospital Medical Information Network - Japan.
    • 22 Dec 2009 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top